Eikon Therapeutics, Inc. (EIKN) stock
Close on Nov 12, 2026Market cap $327.16MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $327.16M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.85
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- $7.09
- Diluted shares
- 54M
Trading
- Previous close
- $6.67
- Open
- $6.78
- Day's range
- $5.84 – $6.82
- Volume
- 735,489
- Average volume (20 days)
- 550,966
- Index membership
- Russell 2000 (since Jun 2026)
- RSI (14 days)
- 43.5
- Volatility (1 year)
- 94.1%
- Relative volume
- 1.46×
On 3 of our idea lists: More cash than they're worth, Insiders buying the dip, Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | EIKN | S&P 500 | Difference | EIKN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -16.8% | -2.7% | −14.1 pts | ||
| 3 months | -42.0% | -1.7% | −40.3 pts |
Two years at a glance
Fiscal years 2024 to 2025, USD
Press releases
Releases Eikon Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
About Eikon Therapeutics
Biological Products, (No Diagnostic Substances)
Eikon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops treatments for oncology indications and neurological diseases. The company utilizes a proprietary technology platform centered on single-molecule tracking to discover therapies, while also in-licensing external clinical assets. Its oncology pipeline features EIK1001, an immune-stimulating dual agonist for melanoma and lung cancer; EIK1003 and EIK1004, selective PARP1 inhibitors for various solid tumors; and EIK1005, a Werner helicase inhibitor. Because its candidates are experimental, the company has no marketed products or commercial customers, focusing its treatments on patient populations participating in clinical studies.
Company profile, executives and historyEikon Therapeutics stock: common questions
What is Eikon Therapeutics's stock price?
EIKN closed at $6.04 on Nov 12, 2026, down 9.45% on the day.
What is Eikon Therapeutics's market cap?
Eikon Therapeutics was worth $327.16M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
Does Eikon Therapeutics pay a dividend?
No. Eikon Therapeutics has not paid a cash dividend over the last twelve months.
How many EIKN shares are sold short?
6M shares were sold short at the latest FINRA report, 14.49% of the float, or 10.5 days of average trading volume.
Who are Eikon Therapeutics's competitors?
Companies most similar to Eikon Therapeutics by business, industry and size include INBX, MOLN, ALEC, RVMD, RLAY.
See a number that looks wrong?